Die Dermagnostix GmbH aus Freiburg, spezialisiert auf die Entwicklung molekulardiagnostischer Tests für dermatologische Fragestellungen, erweitert ihr Leistungsportfolio durch die Übernahme und Fortführung der Fluoreszenzdetektor Technologie der Dialunox GmbH i.L. aus Stockach zum 01.07.2025.
News
Dermagnostix announces acquisition and continuation of the fluorescence detector technology of Dialunox as of July 1st 2025
The Dermagnostix GmbH from Freiburg, specialized on the development of molecular diagnostic tests for dermatology, expands its portfolio by the acquisition and continuation of the fluorescence detector technology of Dialunox GmbH i.L. (Stockach) as of July 1st 2025.
Dermagnostix CEO Prof. Dr. Natalie Garzorz-Stark Wins Innovation Award Dermatology by BVDD e.V.
Natalie Garzorz-Stark, CEO and co-founder of Dermagnostix, has been awarded the Innovation Award Dermatology by BVDD for the groundbreaking approach to revolutionizing dermatological diagnostics with automated molecular tests.
State Parliament President Muhterem Aras and Member of Parliament Nadyne Saint-Cast Visit Dermagnostix in Freiburg
Muhterem Aras and Nadyne Saint-Cast recently visited Dermagnostix. Together with Dermagnostix’ managing directors Natalie Garzorz-Stark and Ludwig Gutzweiler they discussed the challenges and opportunities for healthcare start-ups, highlighting the role of political support for private investments.
Dermagnostix GmbH announces product launch of PsorX®-LabDisk (CE-IVD) after successful pilot customer phase
Dermagnostix announces the official launch of the PsorX®-LabDisk. After the market entry with CE-IVD certification in 2022 and a following successful pilot customer phase, the innovative molecular test for the differential diagnosis of psoriasis and eczema was officially launched in June 2024. The Dermagnostix system consisting of the LabDisk-Analyzer, LabDisk and the Connectivity Solution marks
Next Generation Pathology – Dermagnostix at the DGP Annual Meeting in Munich
“We need this test in our lab!” – it’s hard to imagine a better welcome from a visitor to our booth. Even though we were serving a niche with dermatopathology at the 107th Annual Meeting of the German Society of Pathology (DGP), we were even more pleased about the enthusiasm shown by our booth visitors.
Dermagnostix expands US business development by Eureka Innowwide funding and acceptance into German Accelerator
By participating in several conferences and trade shows in the US – most recently at the ISDP meeting in San Diego – Dermagnostix has already been able to show that the interest in PsorX is high and the feedback is consistently positive. In 2024, the focus will shift even more to business development in the USA. The